Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.

Psychopharmacology - 1 Mar 2007

Gunes Arzu, Scordo Maria Gabriella, Jaanson Peeter, Dahl Marja-Liisa

Abstract excerpt

RATIONALE: Perphenazine, a classical antipsychotic drug, has the potential to induce extrapyramidal side effects (EPS). Dopaminergic and serotonergic pathways are involved in the therapeutic and adverse effects of the drug. OBJECTIVES: To evaluate the impact of polymorphisms in the dopamine D(2) and D(3) and serotonin 2A and 2C receptor genes (DRD2, DRD3, HTR2A, and HTR2C) on short-term effects of perphenazine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Dopamine Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Receptor, Serotonin, 5-HT2A

Share to Receptor, Serotonin, 5-HT2C

Share to Receptors, Dopamine

Share to Receptors, Dopamine D3

Share to Receptors, Serotonin

Source

Identifiers

PMID: 17102980
DOI: 10.1007/s00213-006-0622-x

Genes

DRD2
DRD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.PMID 17102980Read ↗

Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effectsSemantic proximity Read ↗

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.Semantic proximity Read ↗

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.Semantic proximity Read ↗

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effects.Semantic proximity Read ↗

Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.Semantic proximity Read ↗

The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.Semantic proximity Read ↗

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.Semantic proximity Read ↗

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.Semantic proximity Read ↗

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.Semantic proximity Read ↗

Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.